The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•24 February 2026•

1 min read

Gilead Sciences to Acquire Arcellx for $7.8 Billion to Bolster Oncology Pipeline

Key Facts

1Gilead Sciences (GILD) has agreed to acquire Arcellx (ACLX) in a deal valued at $7.8 billion.

2The deal gives Gilead full control over 'anito-cel', a promising cell therapy candidate.

Gilead Sciences (GILD) has officially agreed to acquire Arcellx (ACLX) in a transaction valued at approximately $7.8 billion. This strategic move grants Gilead full ownership of "anito-cel," a highly anticipated cell therapy candidate currently in development. By integrating Arcellx's technology, Gilead aims to significantly strengthen its oncology and cell therapy portfolio to maintain a competitive edge in the biotechnology sector. The acquisition reflects Gilead's broader strategy to diversify its revenue streams beyond its core antiviral business. Market analysts view the deal as a major step in consolidating Gilead's leadership in the rapidly growing gene and cell therapy market. While the $7.8 billion price tag represents a substantial capital outlay, the long-term potential of these advanced therapies offers a promising growth trajectory for the company.